Novavax's shares slid 19% after topline data from a new phase 2 trial on its RSV vaccine fail to impress investors.

BiodVax will test its universal flu vaccine candidate M-001 as a standalone shot after it elicited positive immune responses as a primer in a phase 2b trial.

VBI Vaccines hopes to challenge the hepatitis B vaccine standard-of-care, a position long held by GlaxoSmithKline’s Engerix-B.

Using a painless microneedle patch, scientists are trying to take the "Ow!" out of flu shots.

Chasing a $6 billion market opportunity, Bavarian Nordic reports that a dose of its universal RSV vaccine can elicit a significant immune response.

Six senators are railing on Sanofi for its role in a Zika pricing dustup that’s gained considerable attention since last year.

Declining sales of Prevnar have urged Pfizer to seek compensation elsewhere, including a vaccine against Group B streptococcus.

BiondVax secured a €20 million loan from the European Investment Bank to advance its universal flu vaccine candidate.

R&D